All In Biotech

Drug Trial Radar · NCT01024972

Safety Study of Dantrolene in Subarachnoid Hemorrhage

Dantrolene in the Prevention and Treatment of Cerebral Vasospasm in Subarachnoid Hemorrhage

Last checked: Nov 19, 2026Latest source record: Mar 5, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

31

Actual

Start

Oct 2009

Primary completion

Jul 2013

Study completion Oct 2013

Sponsor

Lead sponsor
University of Massachusetts, WorcesterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
American Heart Association
First posted
Dec 3, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Subarachnoid hemorrhage (SAH) is a devastating acute brain injury due to bleeding onto the brain surface from a ruptured aneurysm. Cerebral vasospasm (cVSP; critical narrowing of brain arteries) is a known complication after SAH and significantly increases disability and death after SAH. Vasospasm is difficult to treat and can lead to stroke. Animal studies have shown that the muscles in the artery wall play a role in cVSP. Dantrolene has been FDA approved and extensively used in clinical practice as a muscle relaxant for more than 30 years. It has been shown to provide some benefit in animal studies of cVSP, as well as in a small number of humans. However, the first human studies have only been observational and over a short period of time. This study will evaluate the safety and tolerability of intravenous dantrolene given every 6 hours over seven days to patients with or at risk for cVSP after SAH. The goal is to determine if future efficacy studies should be done to determine if treatment with Dantrolene may improve the outcome of patients with cVSP after SAH.

Conditions

  • Subarachnoid Hemorrhage
  • Cerebral Vasospasm

Interventions

  • DantroleneDrug

    Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days

  • PlaceboDrug

    equiosmolar volume (5% mannitol) every 6 hours x 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HyponatremiaTime frame: Seven days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UMASS Medical School / UMass Memorial Medical Center

    Worcester, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.